[1]
|
Gibson, B. and Kraus, W.L. (2012) New Insights into the Molecular and Cellular Functions of Poly(ADP-Ribose) and PARPs. Nature Reviews Molecular Cell Biology, 13, 411-424. https://doi.org/10.1038/nrm3376
|
[2]
|
Curtin, N.J. and Szabo C. (2020) Poly(ADP-Ribose) Polymerase Inhibition: Past, Present and Future. Nature Reviews Drug Discov-ery, 19, 711-736. https://doi.org/10.1038/s41573-020-0076-6
|
[3]
|
Lee Kraus, W. (2015) PARPs and ADP-Ribosylation: 50 Years … and Counting. Molecular Cell, 58, 902-910.
https://doi.org/10.1016/j.molcel.2015.06.006
|
[4]
|
Langelier, M.F., Planck, J.L., Roy, S. and Pascal, J.M. (2012) Structural Basis for DNA Damage-Dependent Poly(ADP- ribosyl)ation by Human PARP-1. Science, 336, 728-732. https://doi.org/10.1126/science.1216338
|
[5]
|
Lord, C.J. and Ashworth, A. (2017) PARP Inhibitors: Synthetic Le-thality in the Clinic. Science, 355, 1152-1158.
https://doi.org/10.1126/science.aam7344
|
[6]
|
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., et al. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Na-ture, 434, 917-921.
https://doi.org/10.1038/nature03445
|
[7]
|
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., et al. (2005) Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase. Nature, 434, 913-917.
https://doi.org/10.1038/nature03443
|
[8]
|
Faraoni, I. and Graziani, G. (2018) Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers, 10, Article No. 487. https://doi.org/10.3390/cancers10120487
|
[9]
|
中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用指南[J]. 中国医学前沿杂志(电子版), 2020, 12(5): 29-37.
|
[10]
|
Chauhan, R. and Michalak, T.I. (2020) Kinetics of DNA Damage Repair Response Accompanying Initial Hepadnavirus-Host Genomic Integration in Woodchuck Hepatitis Virus Infection of Hepatocyte. Cancer Genet, 244, 1-10.
https://doi.org/10.1016/j.cancergen.2020.02.001
|
[11]
|
Funato, K., Otsuka, M., Sekiba, K., Miyakawa, Y., Seimiya, T., Shibata, C., et al. (2022) Hepatitis B Virus-Associated Hepatocellular Carcinoma with Smc5/6 Complex Deficiency Is Susceptible to PARP Inhibitors. Biochemical and Biophysical Research Communications, 607, 89-95. https://doi.org/10.1016/j.bbrc.2022.03.137
|
[12]
|
Makokha, G.N., Abe-Chayama, H., Chowdhury, S., Hayes, C.N., Tsuge, M., Yoshima, T., et al. (2019) Regulation of the Hepatitis B Virus Replication and Gene Expression by the Mul-ti-Functional Protein TARDBP. Scientific Reports, 9, Article No. 8462. https://doi.org/10.1038/s41598-019-44934-5
|
[13]
|
Sun, Y., Wu, L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., et al. (2021) Single-Cell Landscape of the Ecosystem in Early-Relapse Hepatocellular Carcinoma. Cell, 184, 404-421.e16. https://doi.org/10.1016/j.cell.2020.11.041
|
[14]
|
Cancer Genome Atlas Research Network (2017) Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 169, 1327-1341.e23. https://doi.org/10.1016/j.cell.2017.05.046
|
[15]
|
Zhang, X., Wang, Y., Gari, A., Qu, C. and Chen, J. (2021) Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Asso-ciation of Its Expression Levels and Immunotherapy Signatures. Frontiers in Immunology, 12, Article ID: 721030. https://doi.org/10.3389/fimmu.2021.721030
|
[16]
|
Li, J., Dou, D., Li, P., Luo, W., Lv, W., Zhang, C., et al. (2017) PARP-1 Serves as a Novel Molecular Marker for Hepatocellular Carcinoma in a Southern Chinese Zhuang Population. Tumor Biology, 39, Article ID: 1010428317706914. https://doi.org/10.1177/1010428317706914
|
[17]
|
Ohri, N., Dawson, L.A., Krishnan, S., Seong, J., Cheng, J.C., Sarin, S.K., et al. (2016) Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. Journal of the National Cancer Institute, 108, djw133.
https://doi.org/10.1093/jnci/djw133
|
[18]
|
Chino, F., Stephens, S.J., Choi, S.S., Marin, D., Kim, C.Y., Morse, M.A., et al. (2018) The Role of External Beam Radiotherapy in the Treatment of Hepatocellular Cancer. Cancer, 124, 3476-3489. https://doi.org/10.1002/cncr.31334
|
[19]
|
Guillot, C., Favaudon, V., Herceg, Z., Sagne, C., Sauvaigo, S., Merle, P., et al. (2014) PARP Inhibition and the Radiosensitizing Effects of the PARP Inhibitor ABT-888 in in Vitro Hepatocellular Carcinoma Models. BMC Cancer, 14, Article No. 603. https://doi.org/10.1186/1471-2407-14-603
|
[20]
|
Gerossier, L., Dubois, A., Paturel, A., Fares, N., Cohen, D., Merle, P., et al. (2021) PARP Inhibitors and Radiation Potentiate Liver Cell Death in Vitro. Do Hepatocellular Carcinomas Have an Achilles’ Heel? Clinics and Research in Hepatology and Gastroenterology, 45, Article ID: 101553. https://doi.org/10.1016/j.clinre.2020.09.014
|
[21]
|
Bishara, L.A., Machour, F.E., Awwad, S.W. and Ayoub, N. (2021) NELF Complex Fosters BRCA1 and RAD51 Recruitment to DNA Damage Sites and Modulates Sensitivity to PARP Inhibition. DNA Repair, 97, Article ID: 103025.
https://doi.org/10.1016/j.dnarep.2020.103025
|
[22]
|
Yang, X.D., Kong, F.E., Qi, L., Lin, J.X., Yan, Q., Loong, J.H.C., et al. (2021) PARP Inhibitor Olaparib Overcomes Sorafenib Resistance through Reshaping the Pluripotent Tran-scriptome in Hepatocellular Carcinoma. Molecular Cancer, 20, Article No. 20. https://doi.org/10.1186/s12943-021-01315-9
|
[23]
|
Xu, H., Ma, Z., Mo, X., Chen, X., Xu, F., Wu, F., et al. (2022) Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. Journal of Cancer, 13, 2226-2237.
https://doi.org/10.7150/jca.66020
|
[24]
|
Dong, Q., Du, Y., Li, H., Liu, C., Wei, Y., Chen, M.K., et al. (2019) EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Research, 79, 819-829.
https://doi.org/10.1158/0008-5472.CAN-18-1273
|
[25]
|
Sen, T., Rodriguez, B.L., Chen, L., Corte, C.M.D., Mori-kawa, N., Fujimoto, J., et al. (2019) Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 9, 646-661. https://doi.org/10.1158/2159-8290.CD-18-1020
|
[26]
|
Zhou, B., Guo, L., Zhang, B., Liu, S., Zhang, K., et al. (2019) Disulfiram Combined with Copper Induces Immunosuppression via PD-L1 Stabilization in Hepatocellular Carcinoma. American Journal of Cancer Research, 9, 2442-2455.
https://doi.org/10.7150/thno.44417
|
[27]
|
Zhou, B., Yan, J., Guo, L., Zhang, B., Liu, S., Yu, M., et al. (2020) He-patoma Cell-Intrinsic TLR9 Activation Induces Immune Escape through PD-L1 Upregulation in Hepatocellular Carcino-ma. Theranostics, 10, 6530-6543.
|
[28]
|
Li, C.X., Shao, Y., Ng, K.T., Liu, X.B., Ling, C.C., Ma, Y.Y., et al. (2012) FTY720 Suppresses Liver Tumor Metastasis by Reducing the Population of Circulating Endothelial Progenitor Cells. PLOS ONE, 7, e32380.
https://doi.org/10.1371/journal.pone.0032380
|
[29]
|
Li, C.X., Wong, B.L., Ling, C.C., Ma, Y.Y., Shao, Y., Geng, W., et al. (2014) A Novel Oxygen Carrier “YQ23” Suppresses the Liver Tumor Metastasis by Decreasing Circulating Endothelial Progenitor Cells and Regulatory T cells. BMC Cancer, 14, Article No. 293. https://doi.org/10.1186/1471-2407-14-293
|
[30]
|
Wang, S., Yang, F.J., Wang, X., Zhou, Y., Dai, B., Han, B., et al. (2017) PARP-1 Promotes Tumor Recurrence after Warm Ischemic Liver Graft Transplantation via Neutrophil Recruit-ment and Polarization. Oncotarget, 8, 88918-88933.
https://doi.org/10.18632/oncotarget.21493
|